Difference between revisions of "Busulfan (Myleran)"
Jump to navigation
Jump to search
m |
m |
||
| Line 27: | Line 27: | ||
[[Category:Alkylating agents]] | [[Category:Alkylating agents]] | ||
[[Category:Irritant chemotherapy]] | [[Category:Irritant chemotherapy]] | ||
| + | |||
| + | [[Category:Acute promyelocytic leukemia medications]] | ||
[[Category:Bone cancer medications]] | [[Category:Bone cancer medications]] | ||
[[Category:Transplant medications]] | [[Category:Transplant medications]] | ||
[[Category:Drugs FDA approved in 1954]] | [[Category:Drugs FDA approved in 1954]] | ||
Revision as of 01:46, 10 November 2014
Also known as Busulfex.
General information
Class/mechanism: Bifunctional alkylating agent which produces guanine-adenine intrastrand crosslinks, inducing apoptosis.[1][2]
Route: IV
Extravasation: irritant
For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias such as Micromedex, Lexicomp, Medscape,UpToDate (courtesy of Lexicomp), or the prescribing information.[1]
Diseases for which it is used
Patient drug information
- Busulfan (Myleran) patient drug information (Chemocare)[3]
- Busulfan (Myleran) patient drug information (UpToDate)[4]
History of changes in FDA indication
- 6/26/1954: Initial FDA approval